首页 News 正文

On August 13th, Zaiding Pharmaceutical announced that the UNITE-1 study of KarXT (Xanomeline Tropium) for schizophrenia has completed the enrollment of all mainland Chinese patients. Zaiding Pharmaceutical is expected to obtain key research data from 2024 to the first half of 2025 and submit a new drug application for KarXT for schizophrenia in mainland China.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

六月清晨搅 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    30